Crossmark

FGF21 gene therapy as treatment for obesity and insulin resistance

Crossref DOI link: https://doi.org/10.15252/emmm.201708791

Published Online: 2018-07-09

Published Print: 2018-08

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Jimenez, Veronica

Jambrina, Claudia

Casana, Estefania

Sacristan, Victor

Muñoz, Sergio

Darriba, Sara

Rodó, Jordi

Mallol, Cristina

Garcia, Miquel

León, Xavier

Marcó, Sara

Ribera, Albert

Elias, Ivet

Casellas, Alba

Grass, Ignasi

Elias, Gemma

Ferré, Tura

Motas, Sandra

Franckhauser, Sylvie

Mulero, Francisca

Navarro, Marc

Haurigot, Virginia

Ruberte, Jesus

Bosch, Fatima https://orcid.org/0000-0002-7705-5515
Funding

Funding for this research was provided by:

Ministerio de Economía y Competitividad (SAF2014‐54866R)

Federación Española de Enfermedades Raras (SAF2014‐54866R)

Generalitat de Catalunya (2014 SGR 1669)

European Commission (PHC‐14‐2015‐667751)

European Foundation for the Study of Diabetes
License Information

Version of Record valid from 2018-07-09
More Information

Publication History

Received: 2017-12-18

Accepted: 2018-06-14

Published: 2018-07-09